Systemic chemotherapy in combination with pericardial window has better outcomes in malignant pericardial effusions

Sezai Çelik, Chiara Lestuzzi, Eugenio Cervesato, Didier Dequanter, Patrizia Piotti, Marzia De Biasio, Massimo Imazio

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Methods Patients treated with systemic CT alone (Group A), CT plus drainage (Group B), or CT plus pericardial window (Group C) were included. Treatment response was defined as complete response (ie, no more pericardial effusion or masses), partial response (ie, reduced total score, without requiring further treatments), stable disease (ie, unchanged total score), or progressive disease (ie, increased total score). Patients with partial or complete response were considered responders.

Results This preliminary report included 175 patients (56.6% male) with a mean age of 54.21 ± 14.26 years. Gender distribution, age, and follow-up duration was similar for all groups (P >.05). Prevalent cancer types were lung cancer (50.9%), breast cancer (14.9%), and lymphoma/leukemia (14.9%). Overall, 22.3%, 42.9%, and 34.9% of patients were in treatment group A, B, and C, respectively. There were 132 responders (75.3%). The rate of responders significantly differed between groups (P

Conclusions Systemic CT plus pericardial window is a more effective treatment option compared with systemic CT alone and systemic CT plus drainage in patients with malignant effusions.

Objective Our aim was to compare systemic chemotherapy (CT) with drainage and with pericardial window in the treatment of neoplastic pericarditis in patients with various malignancies included in the International Neoplastic Pericarditis Treatment study.

Original languageEnglish
Pages (from-to)2288-2293
Number of pages6
JournalJournal of Thoracic and Cardiovascular Surgery
Volume148
Issue number5
DOIs
Publication statusPublished - Nov 1 2014

Fingerprint

Pericardial Effusion
Combination Drug Therapy
Drug Therapy
Drainage
Pericarditis
Lung Neoplasms
Therapeutics
Breast Neoplasms
Age Distribution
Lymphoma
Leukemia
Neoplasms

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Systemic chemotherapy in combination with pericardial window has better outcomes in malignant pericardial effusions. / Çelik, Sezai; Lestuzzi, Chiara; Cervesato, Eugenio; Dequanter, Didier; Piotti, Patrizia; De Biasio, Marzia; Imazio, Massimo.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 148, No. 5, 01.11.2014, p. 2288-2293.

Research output: Contribution to journalArticle

Çelik, Sezai ; Lestuzzi, Chiara ; Cervesato, Eugenio ; Dequanter, Didier ; Piotti, Patrizia ; De Biasio, Marzia ; Imazio, Massimo. / Systemic chemotherapy in combination with pericardial window has better outcomes in malignant pericardial effusions. In: Journal of Thoracic and Cardiovascular Surgery. 2014 ; Vol. 148, No. 5. pp. 2288-2293.
@article{4c23b004104c45fb9d8541de754b0f11,
title = "Systemic chemotherapy in combination with pericardial window has better outcomes in malignant pericardial effusions",
abstract = "Methods Patients treated with systemic CT alone (Group A), CT plus drainage (Group B), or CT plus pericardial window (Group C) were included. Treatment response was defined as complete response (ie, no more pericardial effusion or masses), partial response (ie, reduced total score, without requiring further treatments), stable disease (ie, unchanged total score), or progressive disease (ie, increased total score). Patients with partial or complete response were considered responders.Results This preliminary report included 175 patients (56.6{\%} male) with a mean age of 54.21 ± 14.26 years. Gender distribution, age, and follow-up duration was similar for all groups (P >.05). Prevalent cancer types were lung cancer (50.9{\%}), breast cancer (14.9{\%}), and lymphoma/leukemia (14.9{\%}). Overall, 22.3{\%}, 42.9{\%}, and 34.9{\%} of patients were in treatment group A, B, and C, respectively. There were 132 responders (75.3{\%}). The rate of responders significantly differed between groups (P Conclusions Systemic CT plus pericardial window is a more effective treatment option compared with systemic CT alone and systemic CT plus drainage in patients with malignant effusions.Objective Our aim was to compare systemic chemotherapy (CT) with drainage and with pericardial window in the treatment of neoplastic pericarditis in patients with various malignancies included in the International Neoplastic Pericarditis Treatment study.",
author = "Sezai {\cC}elik and Chiara Lestuzzi and Eugenio Cervesato and Didier Dequanter and Patrizia Piotti and {De Biasio}, Marzia and Massimo Imazio",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.jtcvs.2014.04.031",
language = "English",
volume = "148",
pages = "2288--2293",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Systemic chemotherapy in combination with pericardial window has better outcomes in malignant pericardial effusions

AU - Çelik, Sezai

AU - Lestuzzi, Chiara

AU - Cervesato, Eugenio

AU - Dequanter, Didier

AU - Piotti, Patrizia

AU - De Biasio, Marzia

AU - Imazio, Massimo

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Methods Patients treated with systemic CT alone (Group A), CT plus drainage (Group B), or CT plus pericardial window (Group C) were included. Treatment response was defined as complete response (ie, no more pericardial effusion or masses), partial response (ie, reduced total score, without requiring further treatments), stable disease (ie, unchanged total score), or progressive disease (ie, increased total score). Patients with partial or complete response were considered responders.Results This preliminary report included 175 patients (56.6% male) with a mean age of 54.21 ± 14.26 years. Gender distribution, age, and follow-up duration was similar for all groups (P >.05). Prevalent cancer types were lung cancer (50.9%), breast cancer (14.9%), and lymphoma/leukemia (14.9%). Overall, 22.3%, 42.9%, and 34.9% of patients were in treatment group A, B, and C, respectively. There were 132 responders (75.3%). The rate of responders significantly differed between groups (P Conclusions Systemic CT plus pericardial window is a more effective treatment option compared with systemic CT alone and systemic CT plus drainage in patients with malignant effusions.Objective Our aim was to compare systemic chemotherapy (CT) with drainage and with pericardial window in the treatment of neoplastic pericarditis in patients with various malignancies included in the International Neoplastic Pericarditis Treatment study.

AB - Methods Patients treated with systemic CT alone (Group A), CT plus drainage (Group B), or CT plus pericardial window (Group C) were included. Treatment response was defined as complete response (ie, no more pericardial effusion or masses), partial response (ie, reduced total score, without requiring further treatments), stable disease (ie, unchanged total score), or progressive disease (ie, increased total score). Patients with partial or complete response were considered responders.Results This preliminary report included 175 patients (56.6% male) with a mean age of 54.21 ± 14.26 years. Gender distribution, age, and follow-up duration was similar for all groups (P >.05). Prevalent cancer types were lung cancer (50.9%), breast cancer (14.9%), and lymphoma/leukemia (14.9%). Overall, 22.3%, 42.9%, and 34.9% of patients were in treatment group A, B, and C, respectively. There were 132 responders (75.3%). The rate of responders significantly differed between groups (P Conclusions Systemic CT plus pericardial window is a more effective treatment option compared with systemic CT alone and systemic CT plus drainage in patients with malignant effusions.Objective Our aim was to compare systemic chemotherapy (CT) with drainage and with pericardial window in the treatment of neoplastic pericarditis in patients with various malignancies included in the International Neoplastic Pericarditis Treatment study.

UR - http://www.scopus.com/inward/record.url?scp=84911002620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911002620&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2014.04.031

DO - 10.1016/j.jtcvs.2014.04.031

M3 - Article

VL - 148

SP - 2288

EP - 2293

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 5

ER -